CCCC Analyst Insights | C4 Therapeutics, Inc.

Ratings	Buy	Hold	Sell	Other ratings	Last Close	Average Target	Upside	High Target	Low Target
(m)	(m)	(m)	(m)	(m)	$3.08	(m)	(m)	(m)	(m)

Date	Stock	Analyst	Firm	Price When Rated	Price Target	Upside / Downside	Rating
2026-02-26	CCCC C4 Therapeutics, Inc.	Etzer Darout, PhD, MBA	Barclays	$2.77	$7.00	+152.71%	Overweight
2025-12-17	CCCC C4 Therapeutics, Inc.	Etzer Darout, PhD, MBA	Barclays	$2.43	$5.00	+105.76%	Overweight
2025-09-22	CCCC C4 Therapeutics, Inc.	Etzer Darout, PhD, MBA	Barclays	$3.16	$10.00	+216.46%	Overweight
2025-09-16	CCCC C4 Therapeutics, Inc.	Etzer Darout, PhD, MBA	Barclays	$2.73	$8.00	+193.04%	Overweight

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
FENNEC PHARMACEUTICALS INC. (FENC)	United States	$0.371B	-115.85
Artiva Biotherapeutics, Inc. (ARTV)	United States	$0.367B
Cabaletta Bio, Inc. (CABA)	United States	$0.365B	-2.81
AGENUS INC (AGEN)	United States	$0.383B	1.41
Surrozen, Inc./DE (SRZN)	United States	$0.395B
Zura Bio Ltd (ZURA)		$0.398B	-6.56
Ocugen, Inc. (OCGN)	United States	$0.343B	-6.34
Scribe Therapeutics, Inc. (SCTX)	United States	$0.410B
Editas Medicine, Inc. (EDIT)	United States	$0.424B	-4.29
Kyverna Therapeutics, Inc. (KYTX)	United States	$0.434B	-3.60